Loading patent…
OwnerNicole Deweerd, Mohan Bir Singh +2inventors
InventorsNICOLE DEWEERD, MOHAN BIR SINGH, PREM L. BHALLA, INES SWOBDA
Estimating the term…
The present invention relates generally to reagents useful in the immunotherapeutic or immunoprophylactic treatment of allergic diseases. More particularly, the present invention provides modified allergens exhibiting reduced IgE interactivity including reduced IgE production-stimulatory activity, while retaining T-cell antigenicity, which are useful in the immunomodulation of type I allergic disease conditions. The present invention further contemplates a method of immunomodulation of allergic diseases such as type I allergic disease conditions by the administration of modified allergens exhibiting reduced IgE interactivity while retaining T-cell antigenicity.
1-29. (canceled)
A protein allergen variant selected from the group consisting of an Lol p 5 protein allergen variant, a Phl p 5 protein allergen variant and a Poa p 5 protein allergen variant, wherein the variant comprises a naturally occurring Lol p 5, Phl p 5 or Poa p 5 protein allergen comprising (i) mutations K->N, F->L, T->A, V->A in amino acid residues homologous to the amino acid residues K172, F173, T174 and V175 of SEQ ID NO:
The protein allergen variant of claim 44 comprising amino acids 26-301 of SEQ ID NO:
Dependencies are inferred from the claim text.